Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | PRKCA | P17252 | 2/20 | 0.45 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.45 |
| ▸ | DGKA | P23743 | 1/20 | 0.44 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.43 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | PAM | P19021 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16174232 | 0.90 | ALOX5 (0.58) | ALOX5MAPTDGKALPAR1LPAR3 | |
| SCHEMBL10086062 | 0.90 | ALOX5 (0.58) | ALOX5MAPTDGKALPAR1LPAR3 | |
| SCHEMBL19633080 | 0.90 | TBXA2R (0.49) | ALOX5MAPTDGKALPAR1LPAR3 | |
| SCHEMBL15155990 | 0.88 | ALOX5 (0.45) | ALOX5MAPTPRKCAPRKCEDGKA | |
| SCHEMBL15155555 | 0.88 | ALOX5 (0.45) | ALOX5MAPTPRKCAPRKCEDGKA | |
| SCHEMBL19633081 | 0.86 | ALOX5 (0.54) | ALOX5MAPTDGKALPAR1LPAR3 | |
| SCHEMBL18995350 | 0.86 | ALDH1A1 (0.48) | ALOX5MAPTPRKCAPRKCEDGKA | |
| SCHEMBL15155239 | 0.86 | ALOX5 (0.46) | ALOX5MAPTPRKCAPRKCEDGKA | |
| SCHEMBL15155727 | 0.86 | ALOX5 (0.46) | ALOX5MAPTPRKCAPRKCEDGKA | |
| SCHEMBL15155294 | 0.85 | DNM1 (0.44) | ALOX5MAPTDGKALPAR1LPAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170233734-A1 | NUCLEIC ACID LIPID PARTICLE FORMULATIONS | ALNYLAM PHARMACEUTICALS INC (US) | 2017-08-17 | — | — | US | disclosed |
| US-9687448-B2 | Nucleic acid lipid particle formulations | ALNYLAM PHARMACEUTICALS, INC. (US) | 2017-06-27 | — | — | US | disclosed |
| US-9682922-B2 | Biodegradable lipids for the delivery of active agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2017-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170233734-A1 | NUCLEIC ACID LIPID PARTICLE FORMULATIONS | LIPA, ABHD16A, CETP | ALOX5 369/4885MAPT 3058/4885PRKCA 1505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.